3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Ovarian Neoplasms
4
Carcinoma, Transitional Cell
3
Carcinoma, Non-Small-Cell Lung
3
Urinary Bladder Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Neoplasms
2
Carcinoma, Renal Cell
2
Urologic Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Recurrence
1
Neoplasm Metastasis
1
Microsatellite Instability
1
Lymphoma, Large B-Cell, Diffuse
1
Kidney Neoplasms
1
Kidney Diseases
1
Head and Neck Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Merkel Cell
1
Interventions
Interferon-alpha
7
aldesleukin
6
Sunitinib
6
Radiotherapy
5
Nivolumab
5
Doxorubicin
5
Vincristine
4
Ipilimumab
4
Filgrastim
4
Dactinomycin
4
Chemotherapy, Adjuvant
4
Axitinib
4
cabozantinib
3
Sorafenib
3
Everolimus
3
Etoposide
3
Cyclophosphamide
3
temsirolimus
2
pembrolizumab
2
Ifosfamide
2
G250 monoclonal antibody
2
Fluorouracil
2
Carboplatin
2
Bevacizumab
2
vitespin
1
shark cartilage extract
1
pazopanib
1
lenvatinib
1
glutamic acid diethyl ester
1
cemiplimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Kidney Neoplasms
×
avelumab
×
Clear all
NCT02684006
2025-07-30
JAVELIN Renal 101
Pfizer
Phase 3
Completed
886 enrolled
37 charts
1 FDA